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adjuvant intent. We compared plans with Foward Planning -IMRT (FP–
IMRT) adjusted to the delineated breast volume with two other plans 
without the breast delineated (one with standard tangential beams 
with wedges and another with FP-IMRT). The ACOSOG Z0011 trial 
showed the non inferiority of the irradiation of axillary levels I and II 
(included in the irradiated volume when using standard tangential 
beam radiotherapy to the breast) when compared with axillary 
dissection of the same levels, in selected patients with breast cancer.  
Materials and Methods: We analyzed data from 40 patients 
undergoing radiotherapy after breast conserving surgery, with a 
negative sentinel node biopsy. The patients were submitted to a CT 
for virtual simulation with 3mm slice. The data from the CT were 
doubled. In one CT, 2 dosimetry plans were done: one with 
conventional RT with tangential beams with wedges (2-3 segments 
were added if necessary to achieve dose homogeneity) and another 
with FP-IMRT. On the other CT data, target volumes were delineated: 
breast CTV and PTV (expansions of 10 mm were made for all 
directions except for the posterior one, which was 7 mm), and a plan 
was calculated using the FP-IMRT technique, adjusted to the PTV. We 
then outlined the axillary levels I and II, for analysis, on one CT data 
and copied it to the other. Mean dose (Dmean) and V95 were 
evaluated for axillary levels I and II. The Conformity Index (CI) of the 
PTV was also analysed. 
Results: Both V95 and Dmean for axillary level I were higher in the 
standard tangential beams with wedges technique and in the FP-IMRT 
technique without the breast volume delineated. When compared 
with these plans, the plan adjusted to the breast PTV achieved an 
inferior V95 value to axillary level I. When evaluating the axillary level 
II, these differences were more pronounced. We found a higher CI 
value in the plan adjusted to the breast target volume. 
Conclusions: We found a higher conformity index to the breast target 
volume using the FP-IMRT technique with the breast target volumes 
delineated, and a lower V95 for the axillary levels evaluated. This 
shows that when conforming the dose to the breast alone the 
unintended irradiation of the axilla is lower. Although a higher V95 
was achieved with the standard tangential breast irradiation with 
wedges, it happens at the expenses of a lower conformity index to the 
breast volume, and this technique has shown a higher rate of skin 
toxicity, which lead to being less used. We conclude that the 
delineation of axillary levels I and II is mandatory when there is the 
need to irradiate them, and the information obtained by the sentinel 
node biopsy is therefore important to the radiotherapy treatment. 
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Purpose/Objective: Treatment of locally-advanced rectal cancer with 
neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal 
excision has led to better results in sphincter-preservation and local 
recurrence rates in the last years. Achievement of a pathologic 
complete response (ypT0N0) after nCRT consistently associates to 
improved disease free and overall survival. However, no clinical or 
genetic predictorsof complete response are currently available which 
allow patient stratification and personalization of therapeutic 
strategies. Among the multiple pathways involved in CRT resistance, 
inflammatory response has been demonstrated to mediate both micro-
environmental resistance to radiation damage. To evaluate the role of 
functional polymorphisms of inflammatory response genes (NF-kB, 
Cox-1, Cox-2,IL-1beta) in pathological response to nCRT in rectal 
cancer. 
Materials and Methods: We included patients with locally advanced 
rectal cancer treated with nCRT (capecitabine, 3D pelvic 
radiotherapy, with TD 50.4 Gy) at asingle center. Genomic DNA was 
obtained from peripheral blood or paraffin-embedded non-tumor 
tissue. The following polymorphisms were analyzed with Taqman-
based qPCR: rs28362491(NF-Kβ), rs1213266 (COX-1), rs5789 (COX-1), 
rs20417 (COX-2), rs5275 (COX-2),rs16944 (IL-1β) and rs1143627 (IL-1β). 
Association between genotypes and rectal cancer outcome was 
analyzed with logistic regression models (SNPstatssoftware). 
Results: 159 patients have been included; Patient characteristics: 
median age 65 years, 104%males, 55% female. 95% of population had 
Karnofsky 90-100%; stages IIA (27%), IIIA(4%), IIIB (25%), IIIC (45%). 
Abdominoperineal resection was practiced in 30% and lower anterior 
resection in 70% of cases.Surgery included complete mesorectal 
excision in 78% of patient population.Adjuvant chemotherapy was 
administered in 88% of them. Complete pathological response (pCR) 
rate was 18% and nonresponse in 20%. With a median follow-up of 44 
months (range: 11-93), only 30 patients have recurred with local 
and/ormetastatic disease. Overall survival was 85,4% and desease free 
survival 81%.Univariate analysis shown statistically significant impact 
of NFkB associated to pCR and OS. Distribution of genotypic and allelic 
frequencies for the seven polymorphisms was similar to those 
observed in European populations.  
Conclusions: Our work is the first that analyze the relation between 
inflammation gene polymorphisms and response to nCRT in rectal 
cancer treatment. We did not find significant association between the 
genetic polymorphisms (s1213266, rs5789, rs20417, rs5275, rs16944, 
rs1143627) and the pathological response, but we observed impact of 
NF-Kb in relation between pathological response and overall survival. 
We also observed statistically significant relationship between 
performance status and treatment response. Patients with 100-90% 
Karnofsky have cPR or quasi complete pathological response to nCRT. 
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Purpose/Objective: To prospectively validate the efficacy of 18F-
fluorodeoxyglucose (18F-FDG)-positron emission tomo-graphy (PET)-CT 
imaging for predicting histopathological response and clinical long-
term outcomes in locally advanced rectal cancer (LARC). 
Materials and Methods: 38 patients with confirmed diagnosis of LARC 
(cT3–4 or cN+) were prospectively studied with 18F-FDG PET/CT 
before and after neoadjuvant therapy (NAT). Total mesorectal 
excision (TME) was programmed 6 weeks after NAT followed by an 
expert histopathological analysis of the surgical specimen. Baseline 
variables and previously identified cutoff values of pre-NAT 
(SUVmaxPRE ≥ 6), post-NAT (SUVmaxPOST < 2), absolute (?SUVmax ≥ 4) 
and percentage reduction (?SUVmax ≥ 65%) of the baseline maximum 
FDG standardized uptake value (SUVmax) criteria were applied to 
differentiate metabolic tumor responders from non-responders. These 
features were correlated with disease-free survival (DFS) and overall 
survival (OS).  
Results: 19 responder patients (TRG 3-4) showed a statistically 
significantly higher 5-year disease-free survival (DFS) and overall 
survival (OS) compared with 19 non-responders (TRG0-2) patients 
(94.4 vs 48.8%, p=0.001; 94.7 vs 63.2%, p= 0.02). At multivariate 
analysis the only presurgical parameters correlated to the likelihood 
of recurrence and survival were ?SUV (≥ 65% vs < 65%) [HR= 5.2 
(p=0.01); HR= 4.4 (p=0.03)] and tumor histologic grade (I or II vs III) 
[HR=6.2 (p=0.001); HR= 4.1 (p=0.03)].  
Conclusions: This prospective study has proven that 18F-FDG PET/CT 
is a valuable imaging tool for assessing rectal cancer TRG and long-
term prognosis, and could potentially serve as an intermediate 
endpoint in treatment optimization research and rectal cancer patient 
care. 
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Purpose/Objective: This prospective study evaluates feasibility, 
toxicity and early clinical outcomes of concurrent image guided 
volumetric modulated arc therapy (IG-RA) and weekly cisplatin in the 
setting of a definitive chemoradiotherapy for locally advanced 
esophageal cancer. 
Materials and Methods: 41 Patients diagnosed with squamous cell 
carcinoma of esophagus deemed unsuitable for surgery were included 
in the study. Patients with performance status (ECOG) more than 1, 
involvement of cervical esophagus or gastroesophageal junction, 
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visceral metastasis were excluded from the study. All the patients 
were treated in two phases to a total dose of 5940cGy. Phase I CTV 
(treated to a dose of 45Gy in 25 fractions) was generated by 
expanding the GTV primary cranio-caudally by 4cm and laterally to 
include electively, the corresponding level mediastinal nodes. Phase II 
CTV was generated by expanding the GTV by 2cm craniocaudally and 
1cm radially. Bilateral supraclavicular regions were electively 
included for supracarinal lesions. ITV was generated by expanding the 
CTV by 0.5cm which was then expanded by 0.5cm to yield PTV. IG-RA 
plans consisted of 2 conformal arcs with a high priority to reduce lung 
V20, mean lung dose and heart dose. The set-up was verified by daily 
KV imaging as well as thrice weekly CBCT with oral barium. 
Chemotherapy consisted of 4-6 cycles of weekly cisplatin 40mg/m2. 
Results: The median age of patients was 53 yrs (43-72).The median 
length of involvement of esophagus was 6cm with 80% of the lesions in 
the upper and middle third. 37/41(90%) patients completed planned 
chemotherapy with atleast 4 cycles of cisplatin and 40/41 patients 
completed full dose of radiotherapy. 4/41 (10%) patients required 
tube feeding, 2/41 (5%)patients required hospital admission for 
supportive care but none of the patients had grade IV hematological 
toxicity during treatment. Endoscopy at 8 weeks post treatment was 
performed in 38/41 patients of whom 20 (53%) had CR,16 (42%) had PR 
and 2 (5%) had stable disease locally. With a median follow up of 15 
(6-20) months, 18/41(44%) patients are alive at last follow-up of which 
13 (32%) are disease free with no dysphagia, the 1 and 2 year overall 
survival are 70% and 42% respectively and median survival of 13.5 
months. 3/18 (16%)alive patients have post radiotherapy stricture 
requiring occasional dilatations. Unfortunately none of the patients 
underwent salvage surgery because of various medical and social 
reasons. After analyzing KV image datasets, the modal corrections 
applied for bone matching was 0.1cm (vertical),0.2cm (lateral and 
0.2cm longitudinal. The analysis of CBCT data sets showed that the 
ITV and PTV margins of 0.5cm each were found to be adequate with 
current imaging protocol. 
Conclusions: Image guided volumetric modulated arc therapy to a 
dose of 60Gy with concurrent weekly cisplatin is a feasible treatment 
option for locally advanced inoperable squamous cell carcinoma of 
thoracic esophagus with low acute and late toxicity and with 
promising early clinical outcomes. The ITV and PTV margins of 0.5cm 
were found to be adequate only with image guidance.  
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Purpose/Objective: VEGFR, EGFR, Cox-2 and p53 stimulates key 
processes involved in tumor growth, progression and proliferation, and 
are important targets for cancer therapeutics. Ki-67 is a marker of 
tumor activity.The prognostic and predictive value of these novel 
biomolecular markers expression in association with proliferation in 
selecting targeted agents is currently unknown.The purpose of this 
study was to measure co-expression of EGFR, VEGFR, Cox-2, p53 and 
Ki67 proteins in pre-treatment tumor biopsies of rectal cancer 
patients treated with neoadjuvant treatment and to correlate 
expression with clinical outcome. 
Materials and Methods: EGFR,VEGFR, Cox-2, p53 and Ki67 co-
expression was measured using immunohistochemistry quantitative 
image analysis. Ki67% activity (positive ≥90%) was quantified within 
EGFR, VEGFR, Cox-2 and p53 tumor in high versus low expression. Cox 
proportional hazards models were used to explore associations 
between the tumor markers and disease-free survival (DFS). 
Results: 38 pre-treatment tumors were analyzed. Patients median 
follow-up was 69.3 months (range,4.5-92). Onunivariate analysis, high 
Ki67% activity in VEGFR (HR 4.06 [1.14, 14.43], p =0.03), Cox-2 (HR 
3.89 [1.12, 13.45], p = 0.03); and p53 (HR 4.15 [1.07, 16.07], p Z 0.04) 
high expression tumors was associated with worse DFS. On 
multivariate analysis, only high Ki67% activity in VEGFR high 
expression tumors remained statistically significant forDFS (HR 4.07 
[1.14, 14.3], p = 0.04). 
Conclusions: High Ki67% activity in VEGFR high expression tumors are 
associated with worse DFS in patients with rectal cancer treated with 
induction CT followed by pelvic CRTand surgery. Determination of the 
optimal diagnostic cut-off level for this novel biomarker association 
should be explored. Evaluation within a clinical trial will be required 
to determine whether patients could benefit from an VEGFR targeted 
therapeutic agent. 
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Purpose/Objective: This study investigated the utility of deformable 
image registration in accurately assessing the pattern of local relapse 
with respect to the high dose treatment volume in patients with 
oesophageal cancer following chemoradiation. 
Materials and Methods: Data was collected for 15 patients treated 
between 2009 and 2010. Seven of these patients (46.7%) relapsed; two 
patients (13.3%) had infield recurrence and five (33.3%) experienced 
distant recurrence. All patients were treated with chemoradiation (as 
per the NCRI UK SCOPE trial protocol but not all treated witihin the 
trial) and received conformal radiotherapy of 50Gy in 25 fractions to 
the PTV. This PTV was derived from a CTV based on a CT scan with 
information from un-registered PET-CT and endoscopic ultrasound. 
Retrospectively, deformable image registration was performed 
(Mirada RTx, Mirada Medical, Oxford, UK) between the original 
planning CT and the PET-CT images. Tumour volumes were contoured 
on the PET-CT images and projected onto the original planning CT. In 
addition, for local relapse patients, deformable image registration 
was carried out between the planning CT and the relapse CT images. 
(Figure 1) The site of relapse was contoured and projected onto the 
planning CT. This enabled comparison of the site of relapse relative to 
the planning CT and PET-CT volumes and the dose received by each 
volume to evaluate tumour coverage. Dosimetric analysis was 
undertaken. (Table 1)  
Results: Deformable registration (not rigid body) was necessary to 
accurately transfer relapse CT derived contours to the planning CT as 
the patients typically had different curvature of the spine and 
oesophagus in the PET-CT and diagnostic relapse CT compared to 
planning CT. Of the two local relapses, one was within the PET-CT 
volume whilst the other was in the high dose penumbra (small cell 
oesophageal cancer). This patient died of distant metastatic disease. 
 










4 Patient 5 Patient 6 Patient 7 
GTV 49.99 50.24 49.54 50.24 49.65 50.30 48.86 
CTV or 
CTVa/CTVb48.53 n-a 49.37 49.24 49.58/49.24 48.83/48.99 47.19/47.47
PTV 48.13 49.84 n-a 48.70 48.30 47.03 42.94 
PET 




n-a 8.36 n-a n-a n-a n-a 47.45 
Figure 1: Deformable co-registered image of relapse CT and planning 
CT scan  
 
Black = Original Planning Target Volume 
White = Relapse region 
 
Conclusions: Deformable image registration is a valuable tool that 
allows relapse CT data to be compared accurately to the original 
planning CT and therefore determine if current target definition is 
adequate. Investigation of a larger cohort is required to confirm these 
observations by including this this procedure in the analysis of future 
